The Intracavitary Administration of Radioactive Colloidal Gold

Abstract
IN THE comparatively short time since its introduction by Sheppard and Hahn1 in 1947, radioactive colloidal gold (Au 198) has come to be used frequently in the palliation and treatment of neoplastic disease.2 The increasing importance of this radioactive isotope is due to the clinical usefulness imparted to the material by its particular physical and chemical properties.3 , 4 The isotope is prepared by the irradiation of gold foil in the nuclear reactor pile at Oak Ridge, Tennessee. The foil is converted by aqua regia to gold chloride, which is reduced to metallic gold by ascorbic acid in the presence of excess . . .